4.2 Review

Building a roadmap for developing combination therapies for Alzheimer's disease

Journal

EXPERT REVIEW OF NEUROTHERAPEUTICS
Volume 15, Issue 3, Pages 327-333

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1586/14737175.2015.996551

Keywords

Alzheimer' disease; combination therapy; collaboration; co-development; novel therapy

Funding

  1. Eli Lilly
  2. Eisai
  3. Avid
  4. Janssen
  5. Biogen Idec
  6. Merck Lilly
  7. Roche
  8. Genentech
  9. Alkermes
  10. Forest
  11. FORUM Pharmaceuticals
  12. Lundbeck
  13. Merck
  14. Novartis
  15. Otsuka
  16. Sunovion
  17. Takeda
  18. Toyama
  19. Vanda
  20. Wellcome Trust
  21. IMI
  22. Abbvie
  23. Bayer Healthcare
  24. Boehringer Ingelheim
  25. GSK
  26. Pfizer

Ask authors/readers for more resources

Combination therapy has proven to be an effective strategy for treating many of the world's most intractable diseases. A growing number of investigators in academia, industry, regulatory agencies, foundations and advocacy organizations are interested in pursuing a combination approach to treating Alzheimer's disease. A meeting co-hosted by the Accelerate Cure/Treatments for Alzheimer's Disease Coalition, the Critical Path Institute and the Alzheimer's Association addressed challenges in designing clinical trials to test multiple treatments in combination and outlined a roadmap for making such trials a reality.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available